Literature DB >> 25870277

Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.

Shuo Wang1, Christos Patsis2, Antonis E Koromilas3.   

Abstract

The signal transducer and activator of transcription 1 (Stat1) functions as a tumor suppressor via immune regulatory and cell-autonomous pathways. Herein, we report a previously unidentified cell-autonomous Stat1 function, which is its ability to exhibit both antiproliferative and prosurvival properties by facilitating translation of mRNAs encoding for the cyclin-dependent kinase inhibitor p27(Kip1) and antiapoptotic proteins X-linked inhibitor of apoptosis and B-cell lymphoma xl. Translation of the select mRNAs requires the transcriptional function of Stat1, resulting in the up-regulation of the p110γ subunit of phosphoinositide 3-kinase (PI3K) class IB and increased expression of the translational repressor translation initiation factor 4E (eIF4E)-binding protein 1 (4EBP1). Increased PI3Kγ signaling promotes the degradation of the eIF4A inhibitor programmed cell death protein 4, which favors the cap-independent translation of the select mRNAs under conditions of general inhibition of protein synthesis by up-regulated eIF4E-binding protein 1. As such, Stat1 inhibits cell proliferation but also renders cells increasingly resistant to antiproliferative effects of pharmacological inhibitors of PI3K and/or mammalian target of rapamycin. Stat1 also protects Ras-transformed cells from the genotoxic effects of doxorubicin in culture and immune-deficient mice. Our findings demonstrate an important role of mRNA translation in the cell-autonomous Stat1 functions, with implications in tumor growth and treatment with chemotherapeutic drugs.

Entities:  

Keywords:  Stat1; eIF4E-binding protein 1; mRNA translation; phosphoinositide 3-kinase; programmed cell death protein 4

Mesh:

Substances:

Year:  2015        PMID: 25870277      PMCID: PMC4418918          DOI: 10.1073/pnas.1420671112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  83 in total

1.  SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNγ.

Authors:  Andreas Begitt; Mathias Droescher; Klaus-Peter Knobeloch; Uwe Vinkemeier
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.

Authors:  Charlotte E Edling; Federico Selvaggi; Richard Buus; Tania Maffucci; Pierluigi Di Sebastiano; Helmut Friess; Paolo Innocenti; Hemant M Kocher; Marco Falasca
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

Review 3.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

4.  The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.

Authors:  David Shahbazian; Philippe P Roux; Virginie Mieulet; Michael S Cohen; Brian Raught; Jack Taunton; John W B Hershey; John Blenis; Mario Pende; Nahum Sonenberg
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

5.  STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.

Authors:  Shuo Wang; Jennifer F Raven; Antonis E Koromilas
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

6.  Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis.

Authors:  J A Brazzatti; M Klingler-Hoffmann; S Haylock-Jacobs; Y Harata-Lee; M Niu; M D Higgins; M Kochetkova; P Hoffmann; S R McColl
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

Review 7.  Ras signaling and therapies.

Authors:  Amy Young; Jesse Lyons; Abigail L Miller; Vernon T Phan; Irma Rangel Alarcón; Frank McCormick
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

8.  Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase.

Authors:  Amanda L Martin; Matthew D Schwartz; Stephen C Jameson; Yoji Shimizu
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

9.  STAT1: a modulator of chemotherapy-induced apoptosis.

Authors:  Michelle Thomas; Clodagh E Finnegan; Katherine M-A Rogers; James W Purcell; Anne Trimble; Patrick G Johnston; Marion P Boland
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

10.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Authors:  Juan M García-Martínez; Jennifer Moran; Rosemary G Clarke; Alex Gray; Sabina C Cosulich; Christine M Chresta; Dario R Alessi
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

View more
  4 in total

1.  Long non-coding RNA placenta‑specific protein 2 regulates the chemosensitivity of cancer cells to cisplatin in hepatocellular carcinoma (HCC) by sponging microRNA-96 to upregulate X-linked inhibitor of apoptosis protein.

Authors:  Huixiong Wang; Xin Zhang; Xiaoting Chen; Shengbin Zhang; Zhelin Yun; Qiang Gao; Haitao Sheng; Junjie Wang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  STAT1-mediated translational control in tumor suppression and antitumor therapies.

Authors:  Shuo Wang; Antonis E Koromilas
Journal:  Mol Cell Oncol       Date:  2015-11-13

3.  The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.

Authors:  Ryuhjin Ahn; Valérie Sabourin; Alicia M Bolt; Steven Hébert; Stephanie Totten; Nicolas De Jay; Maria Carolina Festa; Yoon Kow Young; Young Kyuen Im; Tony Pawson; Antonis E Koromilas; William J Muller; Koren K Mann; Claudia L Kleinman; Josie Ursini-Siegel
Journal:  Nat Commun       Date:  2017-03-09       Impact factor: 14.919

Review 4.  Neuroprotective Strategy in Retinal Degeneration: Suppressing ER Stress-Induced Cell Death via Inhibition of the mTOR Signal.

Authors:  Bin Fan; Ying-Jian Sun; Shu-Yan Liu; Lin Che; Guang-Yu Li
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.